Baxdrostat is the first drug to block aldosterone at its source. The FDA just approved it.

What the FDA actually approved

On May 18, 2026, the FDA approved baxdrostat under the brand name Baxfendy. The indication is specific and worth quoting plainly: it is an add-on treatment to lower blood pressure in adults whose hypertension is not adequately controlled on their existing medications. It is not a first-line drug. It is the drug you reach for when the standard regimen has already failed to get the number down. It comes as a once-daily oral tablet in 1 mg and 2 mg strengths, and AstraZeneca expects it on US pharmacy shelves by early June 2026.

The phrase that matters in the FDA announcement is "first-in-class." Baxdrostat is the first aldosterone synthase inhibitor — a drug that targets the enzyme CYP11B2, encoded by the gene of the same name, which the adrenal gland uses to manufacture aldosterone. No approved hypertension drug had ever worked at that exact point in the pathway before. Every other tool that touches aldosterone works one step downstream.

That sounds like a technicality. It is not. It is the reason this approval is a genuine event rather than another line extension, and it is the reason cardiologists who treat hard cases have been watching this molecule for years.

Why blocking the enzyme beats blocking the receptor

Aldosterone is the hormone that tells your kidneys to hold onto sodium and water and dump potassium. Hold onto more sodium and water, and your blood volume rises, and your blood pressure with it. In a meaningful fraction of people with stubborn hypertension, the adrenal gland is simply making too much aldosterone, and that excess is the engine driving the pressure that won't come down.

The existing answer to this is the mineralocorticoid receptor antagonist class — spironolactone and eplerenone. These drugs let aldosterone keep circulating at high levels but block the receptor it would otherwise dock onto. It works. Spironolactone is one of the most effective add-ons in resistant hypertension. But the signal aldosterone carries is only partly silenced, because the hormone is still there, still elevated, still pressing on every other tissue that has a receptor for it. And spironolactone is dirty — it hits the androgen and progesterone receptors too, which is why it produces breast tenderness and gynecomastia in men and menstrual disruption in women often enough to make patients quit.

Baxdrostat works one step earlier. It turns down the enzyme that makes the hormone in the first place, so circulating aldosterone falls rather than just being blocked at one destination. You are not jamming the receptor — you are cutting the supply of the signal at its origin. That is a cleaner intervention in principle, and it sidesteps the sex-hormone side effects that come from spironolactone's lack of selectivity.

Spironolactone blocks the door aldosterone walks through. Baxdrostat shuts off the factory that builds aldosterone. That is the whole difference, and it is not a small one.

The engineering challenge that held this class back for two decades is selectivity. The enzyme that makes aldosterone, CYP11B2, is nearly a structural twin of CYP11B1 — the enzyme that makes cortisol, your primary stress hormone. Hit the wrong one and you knock out cortisol production, which is dangerous. Baxdrostat was designed to be highly selective for CYP11B2 over CYP11B1, and in the trial program that selectivity held up: there were no reported cases of adrenal insufficiency, the failure mode everyone was watching for. That is the breakthrough underneath the approval — not just blocking aldosterone synthesis, but doing it without collateral damage to the cortisol axis.

The aldosterone problem in resistant hypertension

To understand why this drug matters, look at the scale of the problem it targets. Hypertension affects roughly 116 million American adults, and around 92 million of them do not have it controlled. A subset of those — by American Heart Association estimates, on the order of 10 million US adults — have apparent treatment-resistant hypertension: blood pressure that stays high despite three or more drugs, including a diuretic, at adequate doses.

These are the patients who exhaust the playbook. They are on a calcium channel blocker, an ACE inhibitor or ARB, and a thiazide, and the number still won't budge. For a large share of them, the reason is aldosterone excess that the standard three-drug regimen does nothing to address. This is exactly the population baxdrostat was built for, and exactly the population the BaxHTN trial enrolled. Uncontrolled blood pressure is not a cosmetic lab value — it is the single largest modifiable driver of stroke, heart failure, kidney failure, and cardiovascular death. Moving these patients into control is high-stakes.

The BaxHTN trial: the numbers that mattered

The approval rests on BaxHTN, a multinational, randomized, double-blind, placebo-controlled phase 3 trial published in the New England Journal of Medicine in 2025. After a placebo run-in, 796 patients were randomized 1:1:1 to baxdrostat 2 mg, baxdrostat 1 mg, or placebo, once daily, on top of their existing standard-of-care regimen. Patients had to have seated office systolic blood pressure of 140 mmHg or higher despite stable treatment with two drugs (uncontrolled) or three or more drugs including a diuretic (resistant). The majority — 73% — met the stricter resistant-hypertension bar. These were genuinely hard cases.

At 12 weeks, the placebo-adjusted reduction in seated systolic blood pressure was 8.7 mmHg for the 1 mg dose and 9.8 mmHg for the 2 mg dose. From baseline, the 2 mg arm fell 15.7 mmHg and the 1 mg arm fell 14.5 mmHg. Baxdrostat met its primary endpoint and all secondary endpoints.

Put that in clinical context. A placebo-adjusted systolic reduction of roughly 9 to 10 mmHg, in a population that has already failed multiple drugs, is meaningful. Epidemiologically, every 10 mmHg of sustained systolic reduction is associated with a substantial drop in stroke and major cardiovascular events. Getting that magnitude in patients who had nowhere left to go is the result that justified the approval. The 2 mg dose did slightly more than the 1 mg dose — a clean dose-response — and the trade for that extra millimeter or two shows up in the safety data.

The hyperkalemia watch

Here is the number every prescriber will track. Because aldosterone normally drives potassium out of the body, suppressing it does the opposite: potassium goes up. That is the predictable, mechanism-linked risk of any drug in this lane, and it showed up in BaxHTN exactly where you would expect it.

Severe hyperkalemia — blood potassium above 6.0 mmol/L — occurred in 0.4% of placebo patients, 2.3% on baxdrostat 1 mg, and 3.0% on baxdrostat 2 mg. The signal is real and it is dose-dependent. It is also, in absolute terms, manageable: a few percent, in a high-risk population, in a trial setting with monitoring. High potassium is not a nuisance side effect — at the extreme it disrupts heart rhythm — which is why this drug will come with potassium monitoring, particular caution in patients with reduced kidney function, and careful handling alongside ACE inhibitors, ARBs, or potassium-sparing agents that push potassium the same direction. The reassuring half of the safety story is the cortisol axis: no cases of adrenal insufficiency were reported, which is the clearest evidence that the CYP11B2 selectivity held up in humans.

Who this drug is actually for

The label and the trial point at the same patient. Below is the framing I'd use — not a prescribing guide, but the shape of who is and isn't in the picture.

What this approval does not mean

This is not a cure for hypertension, and it is not a replacement for the first-line drugs that already control most people's blood pressure cheaply and safely. The win here is narrow and real: a mechanism that didn't exist in approved form before, aimed at the patients the existing playbook leaves behind.

This is not a green light to ask your doctor to switch you onto the newest pill. If your pressure is controlled, the rational move is to keep doing what's working. New drugs carry the cost of unknowns — the long tail of rare effects that only surfaces once millions of people take a molecule outside the controlled conditions of a trial. That risk is worth taking when the alternative is uncontrolled, organ-damaging pressure. It is not worth taking for the novelty.

And this is not the end of the aldosterone story. Baxdrostat is the first of its class across the FDA line, with a broader trial program — including dedicated studies in different populations — still reading out. The receptor-blockers had a thirty-year head start; the synthase-inhibitors just arrived. For the right patient, that's the part that matters: there is now a tool that works where the old ones didn't, and it cuts the signal at its source instead of jamming the door.